Synapse - Dean Bajorin

Search Within

Dean Bajorin

Results (663)

Paclitaxel, ifosfamide & cisplatin (TIP) as second-line therapy for germ cell tumors (GCT):Long-term follow-up and expansion cohort

Meeting Abstract

Gleeson, J. P.; Knezevic, A.; Bromberg, M.; Patil, S.; Sheinfeld, J.; Carver, B. S.; Jones, D. R.; Bains, M. S.; Bajorin, D. F.; Bosl, G. J.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC)

Meeting Abstract

Bajorin, D. F.; Witjes, J. A.; Gschwend, J.; Schenker, M.; Valderrama, B. P.; Tomita, Y.; Bamias, A.; Lebret, T.; Shariat, S.; Park, S. H.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Pembrolizumab for the treatment of patients with high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin: Extended follow-up of KEYNOTE-057 cohort A

Meeting Abstract

Balar, A. V.; Kamat, A. M.; Kulkarni, G. S.; Uchio, E. M.; Boormans, J. L.; Roumiguie, M.; Krieger, L. E. M.; Singer, E. A.; Bajorin, D. F.; Grivas, P.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma

Journal Article

Teo, M. Y.; Al-Ahmadie, H.; Seier, K.; Tully, C.; Regazzi, A. M.; Pietzak, E.; Solit, D. B.; Tickoo, S.; Reuter, V.; Cha, E. K.; more...
British Journal of Cancer (2021)

Fulltext@MSK | Save

A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract

Journal Article

Sarfaty, M.; Whiting, K.; Teo, M. Y.; Lee, C. H.; Peters, V.; Durocher, J.; Regazzi, A. M.; McCoy, A. S.; Hettich, G.; Jungbluth, A. A.; more...
Cancer Medicine (2021)

Fulltext@MSK | Save

MSK-ACCESS for the detection of fibroblast growth factor receptor-3 (FGFR3) mutations in plasma cell-free (cf)DNA of metastatic urothelial carcinoma (mUC) patients (pts) pre- and on erdafitinib (erda) therapy

Meeting Abstract

Sarfaty, M.; Teo, M. Y.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Ratna, N.; Regazzi, A. M.; Al-Ahmadie, H.; Brannon, A. R.; Berger, M. F.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Oncologic therapy shapes the fitness landscape of clonal hematopoiesis

Meeting Abstract

Bolton, K. L.; Ptashkin, R. N.; Gao, T.; Braunstein, L.; Devlin, S. M.; Patel, M.; Berthon, A.; Syed, A.; Yabe, M.; Coombs, C.; more...
Cancer Research (2020)

Fulltext@MSK | Save

Rationale and outcomes for neoadjuvant immunotherapy in urothelial carcinoma of the bladder

Review

Rouanne, M.; Bajorin, D. F.; Hannan, R.; Galsky, M. D.; Williams, S. B.; Necchi, A.; Sharma, P.; Powles, T.
European Urology Oncology (2020)

Fulltext@MSK | Save

Five-factor prognostic model for survival of post-platinum patients with metastatic urothelial carcinoma receiving PD-L1 inhibitors

Journal Article

Sonpavde, G.; Manitz, J.; Gao, C.; Tayama, D.; Kaiser, C.; Hennessy, D.; Makari, D.; Gupta, A.; Abdullah, S. E.; Niegisch, G.; more...
Journal of Urology (2020)

Fulltext@MSK | Save

Hyperphosphatemia secondary to the selective fibroblast growth factor receptor 1–3 inhibitor infigratinib (BGJ398) is associated with antitumor efficacy in fibroblast growth factor receptor 3–altered advanced/metastatic urothelial carcinoma

Journal Article

Lyou, Y.; Grivas, P.; Rosenberg, J. E.; Hoffman-Censits, J.; Quinn, D. I.; Petrylak, D. P.; Galsky, M.; Vaishampayan, U.; De Giorgi, U.; Gupta, S.; more...
European Urology (2020)

Fulltext@MSK | Save